Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: committee papers

Table of contents:

1 Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

2 Consultee and commentator comments on the ACD from Janssen

3 Consultee and commentator comments on the ACD from PAPAA

4 Consultee and commentator comments on the ACD from Psoriasis Association

5 Consultee and commentator comments on the ACD from the Royal College of Nursing

6 Consultee and commentator comments on the ACD from AbbVie

This page was last updated: 09 March 2015